1547 related articles for article (PubMed ID: 28055269)
21. Immune Checkpoint Inhibitors in Lung Cancer: Imaging Considerations.
Wang GX; Guo LQ; Gainor JF; Fintelmann FJ
AJR Am J Roentgenol; 2017 Sep; 209(3):567-575. PubMed ID: 28657846
[TBL] [Abstract][Full Text] [Related]
22. Perspectives on Treatment of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitor Therapy.
Morse MA; Hochster H; Benson A
Oncologist; 2020 Jan; 25(1):33-45. PubMed ID: 31383813
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapy for Esophageal and Gastric Cancer.
Kelly RJ
Am Soc Clin Oncol Educ Book; 2017; 37():292-300. PubMed ID: 28561677
[TBL] [Abstract][Full Text] [Related]
24. [Development of immune checkpoint inhibitors].
Kitano S
Rinsho Ketsueki; 2017; 58(8):966-976. PubMed ID: 28883282
[TBL] [Abstract][Full Text] [Related]
25. Immune Checkpoint Inhibition in Gastro-Oesophageal Cancer.
Smyth E; Thuss-Patience PC
Oncol Res Treat; 2018; 41(5):272-280. PubMed ID: 29705787
[TBL] [Abstract][Full Text] [Related]
26. Immunotherapy in Gastroesophageal Cancers: Current Evidence and Ongoing Trials.
Huynh J; Patel K; Gong J; Cho M; Malla M; Parikh A; Klempner S
Curr Treat Options Oncol; 2021 Sep; 22(11):100. PubMed ID: 34524553
[TBL] [Abstract][Full Text] [Related]
27. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
McArthur HL; Page DB
Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
[TBL] [Abstract][Full Text] [Related]
29. Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology.
Barbee MS; Ogunniyi A; Horvat TZ; Dang TO
Ann Pharmacother; 2015 Aug; 49(8):907-37. PubMed ID: 25991832
[TBL] [Abstract][Full Text] [Related]
30. PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
Grigg C; Rizvi NA
J Immunother Cancer; 2016; 4():48. PubMed ID: 27532023
[TBL] [Abstract][Full Text] [Related]
31. Anti-PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy.
Valecha GK; Vennepureddy A; Ibrahim U; Safa F; Samra B; Atallah JP
Expert Rev Anticancer Ther; 2017 Jan; 17(1):47-59. PubMed ID: 27841044
[TBL] [Abstract][Full Text] [Related]
32. A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors.
Verma V; Sprave T; Haque W; Simone CB; Chang JY; Welsh JW; Thomas CR
J Immunother Cancer; 2018 Nov; 6(1):128. PubMed ID: 30470252
[TBL] [Abstract][Full Text] [Related]
33. Systematic Review of Immune Checkpoint Inhibition in Urological Cancers.
Rijnders M; de Wit R; Boormans JL; Lolkema MPJ; van der Veldt AAM
Eur Urol; 2017 Sep; 72(3):411-423. PubMed ID: 28645491
[TBL] [Abstract][Full Text] [Related]
34. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.
Nishijima TF; Shachar SS; Nyrop KA; Muss HB
Oncologist; 2017 Apr; 22(4):470-479. PubMed ID: 28275115
[TBL] [Abstract][Full Text] [Related]
35. Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue.
Varricchi G; Marone G; Mercurio V; Galdiero MR; Bonaduce D; Tocchetti CG
Curr Med Chem; 2018; 25(11):1327-1339. PubMed ID: 28403786
[TBL] [Abstract][Full Text] [Related]
36. Advances in the Treatment of Non-small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab.
Leventakos K; Mansfield AS
BioDrugs; 2016 Oct; 30(5):397-405. PubMed ID: 27411930
[TBL] [Abstract][Full Text] [Related]
37. Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab.
Passiglia F; Galvano A; Rizzo S; Incorvaia L; Listì A; Bazan V; Russo A
Int J Cancer; 2018 Mar; 142(6):1277-1284. PubMed ID: 29080213
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy in head and neck cancer: aiming at EXTREME precision.
Szturz P; Vermorken JB
BMC Med; 2017 Jun; 15(1):110. PubMed ID: 28571578
[TBL] [Abstract][Full Text] [Related]
39. Esophageal, gastric cancer and immunotherapy: small steps in the right direction?
Zayac A; Almhanna K
Transl Gastroenterol Hepatol; 2020; 5():9. PubMed ID: 32190777
[TBL] [Abstract][Full Text] [Related]
40. The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability
Jin Z; Yoon HH
J Gastrointest Oncol; 2016 Oct; 7(5):771-788. PubMed ID: 27747091
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
